BridgeBio says real-world EHR study links acoramidis to 18% lower composite risk vs tafamidis in ATTR-CM

• BridgeBio reported new real-world evidence, already presented at HFSA ASM 2026, comparing its ATTR-CM drug acoramidis with Pfizer’s tafamidis.
• An independent U.S. electronic health records analysis linked acoramidis to better overall clinical outcomes, driven mainly by fewer hospitalizations.
• Mortality trended in acoramidis’ favor but was not conclusive, reflecting limited follow-up in this early post-launch dataset.
• Management framed the findings as reinforcing acoramidis’ positioning as a preferred transthyretin stabilizer, including for patients switching therapies.
• The full electronic health record study is under journal peer review, with additional updates planned as longer-term data accumulate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610111430PRIMZONEFULLFEED9843416) on October 11, 2026, and is solely responsible for the information contained therein.